| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Analysis of cluster randomised trials as if they were individually randomised
|
Bolland, Mark J
|
|
|
11 |
2 |
p. 75
|
artikel
|
| 2 |
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply
|
Jolliffe, David A
|
|
|
11 |
2 |
p. 75-76
|
artikel
|
| 3 |
Blood lipids after COVID-19 infection
|
Durrington, Paul
|
|
|
11 |
2 |
p. 68-69
|
artikel
|
| 4 |
Clinical use of continuous glucose monitoring in type 1 diabetes
|
Nørgaard, Kirsten
|
|
|
11 |
2 |
p. 65-67
|
artikel
|
| 5 |
Correction to Lancet Diabetes Endocrinol 2022; 10: 859–68
|
|
|
|
11 |
2 |
p. e2
|
artikel
|
| 6 |
Diabetes educators: rewriting the narrative
|
Koch, Marta
|
|
|
11 |
2 |
p. 85
|
artikel
|
| 7 |
Diabetes registries and high-quality diabetes care
|
Khunti, Kamlesh
|
|
|
11 |
2 |
p. 70-72
|
artikel
|
| 8 |
Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial
|
Visser, Margaretha M
|
|
|
11 |
2 |
p. 96-108
|
artikel
|
| 9 |
Glucagon, from past to present: a century of intensive research and controversies
|
Scheen, André J
|
|
|
11 |
2 |
p. 129-138
|
artikel
|
| 10 |
Hot topics on insulin access: pricing in the USA
|
Burki, Talha
|
|
|
11 |
2 |
p. 82-84
|
artikel
|
| 11 |
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled, non-inferiority trial
|
Mathiesen, Elisabeth R
|
|
|
11 |
2 |
p. 86-95
|
artikel
|
| 12 |
Insulin products and patents in the USA in 2004, 2014, and 2020: a cross-sectional study
|
Van de Wiele, Victor L
|
|
|
11 |
2 |
p. 73-75
|
artikel
|
| 13 |
Insulin regimens during type 1 diabetes pregnancy
|
Murphy, Helen R
|
|
|
11 |
2 |
p. 64-65
|
artikel
|
| 14 |
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
|
Ray, Kausik K
|
|
|
11 |
2 |
p. 109-119
|
artikel
|
| 15 |
May Ng: a lifetime commitment to children
|
Power, Carl
|
|
|
11 |
2 |
p. 81
|
artikel
|
| 16 |
ORION-3: delivering lipid lowering treatment for longer
|
Nicholls, Stephen J
|
|
|
11 |
2 |
p. 67-68
|
artikel
|
| 17 |
Risks and burdens of incident dyslipidaemia in long COVID: a cohort study
|
Xu, Evan
|
|
|
11 |
2 |
p. 120-128
|
artikel
|
| 18 |
Teplizumab approval for type 1 diabetes in the USA
|
Beran, David
|
|
|
11 |
2 |
p. 78-80
|
artikel
|
| 19 |
Teplizumab approval for type 1 diabetes in the USA
|
Evans-Molina, Carmella
|
|
|
11 |
2 |
p. 76-77
|
artikel
|
| 20 |
Teplizumab approval for type 1 diabetes in the USA
|
Kordonouri, Olga
|
|
|
11 |
2 |
p. 77-78
|
artikel
|
| 21 |
The voices of lived experience in diabetes and endocrinology
|
The Lancet Diabetes & Endocrinology,
|
|
|
11 |
2 |
p. 63
|
artikel
|
Tijdschrift beschrijving